Drug labels must now reveal where ingredients come from—in five years
S. 3788 — CLEAR LABELS Act · Filed by Rick Scott (R-FL) · 12 cosponsors · Introduced Feb 5, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires drug manufacturers to label all medications with the name and location of the original manufacturer of active ingredients and finished products, plus any packers or distributors. The FDA can fine companies up to 25% of a drug lot's value for non-compliance, though it must consider company size, prior notice, and good-faith correction efforts. The requirement takes effect 5 years after enactment.
Why we flagged it
The bill's core mechanism is a labeling requirement designed to increase public visibility into pharmaceutical sourcing and manufacturing origins. This is a transparency and consumer-protection measure, not a subsidy, carve-out, or deregulation.
What the text implies
- The 5-year phase-in may allow manufacturers to clear existing inventory without compliance, delaying full transparency benefits for half a decade.
- FDA discretion to treat noncompliance as 'misbranding' rather than mandatory criminal violation may result in inconsistent enforcement depending on agency priorities and resources.
The full analysis lists 5 implications of this text.
Who stands to gain
Domestic pharmaceutical manufacturers (compliance cost offset by competitive advantage in transparen; Pharmaceutical supply chain software vendors (tracking and labeling systems); Contract manufacturers with clear ownership of manufacturing phases (reduced ambiguity under the bil